Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS
$3.46
-0.11 (-3.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $127.0M · quality 80.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$570M
P/E
5.6x
↓EV/EBITDA
9.0x
↓ROE
-9.2%
↓Gross Margin
N/A
•Debt/Equity
-2.28
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+14.4%
FCF CAGR
—
FCF margin
42.9%
FCF / Net income
5.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $296.2M · net income $24.0M · FCF $127.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $296.2M | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M | $389.5M | $428.4M | $346.6M | $298.3M | $274.0M | $149.6M | $76.4M | $22.9M | $150.2M | $65.9M | $43.9M | $34.3M |
| Net Income | $24.0M | $24.0M | $880000.00 | $-1.00B | $175.1M | $528.4M | $106.2M | $21.5M | $-282.4M | $-116.9M | $-81.7M | $-142.7M | $-189.6M | $-272.8M | $-72.6M | $-64.9M | $-51.9M | $-73.3M |
| EBITDA | $104.7M | $104.7M | $100.2M | $-924.9M | $261.4M | $233.8M | $145.2M | $125.7M | $-146.8M | $-9.0M | $-41.6M | $-90.5M | $-157.0M | $-240.3M | $-61.4M | $-56.1M | $-54.6M | $-56.1M |
| EPS | 0.15 | 0.15 | 0.01 | -6.45 | 0.96 | 3.21 | 0.66 | 0.14 | -1.85 | — | — | — | — | -1.97 | -0.57 | -0.54 | — | — |
| Gross Margin | — | — | — | — | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 40.1% | 40.1% | 27.2% | 38.0% | 61.0% | 56.1% | 36.7% | 28.0% | -43.5% | -5.2% | -18.9% | -68.3% | -221.6% | -1101.4% | -48.4% | -100.4% | -138.6% | -177.2% |
| Net Margin | 8.1% | 8.1% | 0.3% | -226.4% | 42.6% | 127.7% | 27.3% | 5.0% | -81.5% | -39.2% | -29.8% | -95.4% | -248.1% | -1192.3% | -48.3% | -98.5% | -118.2% | -213.6% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | -2.28 | -2.28 | -1.99 | -2.07 | 0.64 | 0.75 | 6.87 | — | — | — | — | 2.32 | — | — | — | — | — | — |
| Current Ratio | 1.41 | 1.41 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $127.0M | $127.0M | $103.4M | $183.2M | $273.6M | $261.6M | $167.0M | $3.5M | $-71.2M | $-103.6M | $-30.1M | $-111.0M | $-159.1M | $-282.9M | $-83.6M | $-84.9M | $-85.1M | $-7.0M |
| Returns | ||||||||||||||||||
| ROE | -9.2% | -9.2% | -0.3% | 289.4% | 26.8% | 87.2% | 169.5% | -23.1% | 143.8% | -1187.4% | -122.5% | -150.0% | -214.1% | -713.7% | -50.4% | -59.0% | -32.5% | — |
| Valuation | ||||||||||||||||||
| P/E | 5.58 | 5.58 | 451.00 | — | 13.08 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 9.04 | 9.04 | 12.30 | — | 8.03 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | — | — | — | — | 3.59 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -15.7% | -15.7% | -20.6% | 7.8% | — | 6.2% | -9.1% | 23.6% | 16.2% | 8.9% | 83.2% | 95.7% | 234.1% | -84.8% | 128.1% | 50.2% | 27.8% | — |
| EPS Growth | 1400.0% | 1400.0% | 100.2% | -771.9% | — | 386.4% | 371.4% | 107.6% | — | — | — | — | — | -245.6% | -4.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
27.0%
EPS terminal req.
$0.31
Spread vs growth
1373.0%
5Y implied EPS CAGR
19.9%
EPS terminal req.
$0.37
Spread vs growth
1380.1%
10Y implied EPS CAGR
14.8%
EPS terminal req.
$0.60
Spread vs growth
1385.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+476.7%
Start / end P/E
60.0x → 23.1x
EPS bridge
0.01 → 0.15
Residual
-861.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.